Prokineticin 2 and Prokineticin Receptor 2 as a Target to Treat Epilepsy and Seizures
Researchers at the University of California have found that PK2 is an important regulator of seizure onset and epilepsy. A PKR2 modulator would thus help treat epileptic patients and/or patients suffering from non-epileptic seizures. Certain materials such as cDNAs and cell lines that may be used as screening and research tools are readily available for licensing. This technology is also available for sponsor research opportunities.
Patent Number: US8101158B1
Application Number: US200825673A
Inventor: Zhou, Qun-Yong | Lee, Alex G. | Cheng, Michelle Y. | Sapolsky, Robert M.
Priority Date: 2 Feb 2007
Priority Number: US8101158B1
Application Date: 4 Feb 2008
Publication Date: 24 Jan 2012
IPC Current: A61K004900 | A61K0031535
US Class: 4240091 | 5142312
Assignee Applicant: The Regents of the University of California
Title: Methods for treating cerebrovascular disease comprising administering an agent that inhibits prokineticin receptor activity
Usefulness: Methods for treating cerebrovascular disease comprising administering an agent that inhibits prokineticin receptor activity
Summary: The method is useful for treating cerebrovascular diseases in a subject, preferably mammal or human, including cerebral ischemia (all claimed), cerebral hemorrhage, ischemic stroke, hemorrhagic stroke, ischemic reperfusion injury, seizure disorders, and epilepsy. Tests details are described but no results given.
Novelty: Treating cerebrovascular disease in subject, comprises administering prokineticin receptor antagonist, where infarct size is reduced as compared to infarct size without administration of the antagonist
Disease Diagnostic/Treatment
Other Disease
8101158
Tech ID/UC Case 18757/2007-293-0 Related Cases 2007-293-0
USA
